Marine-Derived Fungal Metabolites References 783
Part F | 32
32.17
D. Mendola: Aquaculture production of bryostatin 1 and ecteinascidin 743. In: Drugs from the
Sea, ed. by N. Fusetani (Karger, Basel 2000) pp.
120–133
32.18
D. Mendola: Aquaculture of three phyla of marine
invertebrates to yield bioactive metabolites: Process developments and economies, Biomol. Eng.
20, 441–458 (2003)
32.19
C. Cuevas, M. Pérez, M.J. Martín, J.L. Chicharro,
C. Fernández-Rivas, M. Flores, A. Francesch,
P. Gallego, M. Zarzuelo, F. de La Calle, J. García,
C. Polanco, I. Rodríguez, I. Manzanares: Synthesis of ecteinascidin ET-743 and phthalascidin
Pt-650 from cyanosafracin B, Org. Lett. 2, 2545–
2548 (2000)
32.20
D. Uemura, K. Takahashi, T. Yamamoto: Norhalichondrin A: An antitumor polyether macrolide
from a marine sponge, J. Am. Chem. Soc. 107,
4796–4798 (1985)
32.21
Y. Hirata, D. Uemura: Halichondrins–antitumor
polyether macrolides from a marine sponge, Pure
Appl. Chem. 58, 701–710 (1986)
32.22
G.R. Pettit: The dolastatins, Prog. Chem. Org. Nat.
Prod. 70, 1–79 (1997)
32.23
R. Bai, G.R. Pettit, E. Hamel: Dolastatin 10, a powerful cytostatic peptide derived from a marine
animal – Inhibition of tubulin polymerization
mediated through the vinca alkaloid binding domain, Biochem. Pharmacol. 39, 1941–1949 (1990)
32.24
R. Bai, G.R. Pettit, E. Hamel: Binding of dolastatin
10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide
and vinca alkaloid sites, J. Biol. Chem. 265, 17141–
17149 (1990)
32.25
S.O. Doronina, B.E. Toki, M.Y. Torgov, B.A. Mendelsohn, C.G. Cerveny, D.F. Chace, R.L. DeBlanc,
R.P. Gearing, T.D. Bovee, C.B. Siegall, J.A. Francisco, A.F. Wahl, D.L. Meyer, P.D. Senter: Development of potent monoclonal antibody auristatin
conjugates for cancer therapy, Nature Biotechnol.
21, 778–784 (2003)
32.26
J.A. Francisco, C.G. Cerveny, D.L. Meyer, B.J. Mixan,
K. Klussman, D.F. Chace, S.X. Rejniak, K.A. Gordon, R. DeBlanc, B.E. Toki, C.-L. Law, S.O. Doronina, C.B. Siegall, P.D. Senter, A.F. Wahl: cAC10vcMMAE, an anti-CD30-monomethyl auristatin E
conjugate with potent and selective antitumor
activity, Blood 102, 1458–1465 (2003)
32.27
A. Younes, U. Yasothan, P. Kirkpatrick: Brentuximab vedotin, Nat. Rev. Drug Discov. 11, 19–20
(2012)
32.28
K.L. Rinehart, A.M. Lithgow-Bertelloni: Dehydrodidemnin B, WO9104985 (1991)
32.29
K.L. Rinehart, J.B. Gloer, J.C. Cook, S.A. Mizsak,
T.A. Scahill: Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Caribbean
tunicate, J. Am. Chem. Soc. 103, 1857–1859 (1981)
32.30
O. Kucuk, M.L. Young, T.M. Habermann, B.C. Wolf,
J. Jimeno, P.A. Cassileth: Phase II trial of didemnin
B in previously treated non-Hodgkin’s lymphoma: An Eastern cooperative oncology group
(ECOG) study, Am. J. Clin. Oncol. 23, 273–277
(2000)
32.31
B. Nuijen, M. Bouma, C. Manada, J.M. Jimeno,
J.H.M. Schellens, A. Bult, J.H. Beijnen: Pharmaceutical development of anticancer drugs derived
from marine sources, Anticancer Drugs 11, 793–811
(2000)
32.32
C.S. Mitsiades, E.M. Ocio, A. Pandiella, P. Maiso,
C. Gajate, M. Garayoa, D. Vilanova, J.C. Montero, N. Mitsiades, C.J. McMullan, N.C. Munshi,
T. Hideshima, D. Chauhan, P. Aviles, G. Otero,
G. Faircloth, M.V. Mateos, P.G. Richardson,
F. Mollinedo, J.F. San-Miguel, K.C. Anderson:
Aplidin, a marine organism-derived compound
with potent antimyeloma activity in vitro and in
vivo, Cancer Res. 68, 5216–5225 (2008)
32.33
C. Le Tourneau, E. Raymond, S. Faivre: Aplidine: A
paradigm of how to handle the activity and toxicity of a novel marine anticancer poison, Curr.
Pharm. Des. 13, 3427–3439 (2007)
32.34
W. Kem, F. Soti, K. Wildeboer, S. LeFrancois,
L. MacDougall, D.-Q. Wei, K.-C. Chou, H.R. Arias:
The nemertine toxin anabaseine and its deriative
DMXBA (GTS-21): Chemical and pharmacological
properties, Mar. Drugs 4, 255–273 (2006)
32.35
J.J. Buccafusco, S.R. Letchworth, M. Bencherif,
P.M. Lippiello: Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic
discordance, Trends Pharmacol. Sci. 26, 352–360
(2005)
32.36
H. Kitagawa, T. Takenouchi, R. Azuma, K.A. Wesnes, W.G. Kramer, D.E. Clody, A.L. Burnett: Safety,
pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male
volunteers, Neuropsychopharmacology 28, 542–
551 (2003)
32.37
A. Olincy, J.G. Harris, L.L. Johnson, V. Pender,
S. Kongs, D. Allensworth, K. Ellis, G.O. Zerbe,
S. Leonard, K.E. Stevens, J.O. Stevens, L. Martin, L.E. Adler, F. Soti, W.R. Kem, R. Freedman:
Proof-of-concept trial of an ˛7 nicotinic agonist
in schizophrenia, Arch. Gen. Psychiatr. 63, 630–
638 (2006)
32.38
R. Freedman, A. Olincy, R.W. Buchanan, J.G. Harris, J.M. Gold, L. Johnson, D. Allensworth,
A. Guzman-Bonilla, B. Clement, M.P. Ball, J. Kutnick, V. Pender, L.F. Martin, K.E. Stevens,
B.D. Wagner, G.O. Zerbe, F. Soti, W.R. Kem: Initial
Phase 2 trial of a nicotinic agonist in schizophrenia, Am. J. Psych. 165, 1040–1047 (2008)
32.39
B. Nicholson, G.K. Lloyd, B.R. Miller, M.A. Palladino, Y. Kiso, Y. Hayashi, S.T. Neuteboom:
NPI-2358 is a tubulin-depolymerizing agent: invitro evidence for activity as a tumor vasculardisrupting agent, Anticancer Drugs 17, 25–31
(2006)
Part F | 32
32.17
D. Mendola: Aquaculture production of bryostatin 1 and ecteinascidin 743. In: Drugs from the
Sea, ed. by N. Fusetani (Karger, Basel 2000) pp.
120–133
32.18
D. Mendola: Aquaculture of three phyla of marine
invertebrates to yield bioactive metabolites: Process developments and economies, Biomol. Eng.
20, 441–458 (2003)
32.19
C. Cuevas, M. Pérez, M.J. Martín, J.L. Chicharro,
C. Fernández-Rivas, M. Flores, A. Francesch,
P. Gallego, M. Zarzuelo, F. de La Calle, J. García,
C. Polanco, I. Rodríguez, I. Manzanares: Synthesis of ecteinascidin ET-743 and phthalascidin
Pt-650 from cyanosafracin B, Org. Lett. 2, 2545–
2548 (2000)
32.20
D. Uemura, K. Takahashi, T. Yamamoto: Norhalichondrin A: An antitumor polyether macrolide
from a marine sponge, J. Am. Chem. Soc. 107,
4796–4798 (1985)
32.21
Y. Hirata, D. Uemura: Halichondrins–antitumor
polyether macrolides from a marine sponge, Pure
Appl. Chem. 58, 701–710 (1986)
32.22
G.R. Pettit: The dolastatins, Prog. Chem. Org. Nat.
Prod. 70, 1–79 (1997)
32.23
R. Bai, G.R. Pettit, E. Hamel: Dolastatin 10, a powerful cytostatic peptide derived from a marine
animal – Inhibition of tubulin polymerization
mediated through the vinca alkaloid binding domain, Biochem. Pharmacol. 39, 1941–1949 (1990)
32.24
R. Bai, G.R. Pettit, E. Hamel: Binding of dolastatin
10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide
and vinca alkaloid sites, J. Biol. Chem. 265, 17141–
17149 (1990)
32.25
S.O. Doronina, B.E. Toki, M.Y. Torgov, B.A. Mendelsohn, C.G. Cerveny, D.F. Chace, R.L. DeBlanc,
R.P. Gearing, T.D. Bovee, C.B. Siegall, J.A. Francisco, A.F. Wahl, D.L. Meyer, P.D. Senter: Development of potent monoclonal antibody auristatin
conjugates for cancer therapy, Nature Biotechnol.
21, 778–784 (2003)
32.26
J.A. Francisco, C.G. Cerveny, D.L. Meyer, B.J. Mixan,
K. Klussman, D.F. Chace, S.X. Rejniak, K.A. Gordon, R. DeBlanc, B.E. Toki, C.-L. Law, S.O. Doronina, C.B. Siegall, P.D. Senter, A.F. Wahl: cAC10vcMMAE, an anti-CD30-monomethyl auristatin E
conjugate with potent and selective antitumor
activity, Blood 102, 1458–1465 (2003)
32.27
A. Younes, U. Yasothan, P. Kirkpatrick: Brentuximab vedotin, Nat. Rev. Drug Discov. 11, 19–20
(2012)
32.28
K.L. Rinehart, A.M. Lithgow-Bertelloni: Dehydrodidemnin B, WO9104985 (1991)
32.29
K.L. Rinehart, J.B. Gloer, J.C. Cook, S.A. Mizsak,
T.A. Scahill: Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Caribbean
tunicate, J. Am. Chem. Soc. 103, 1857–1859 (1981)
32.30
O. Kucuk, M.L. Young, T.M. Habermann, B.C. Wolf,
J. Jimeno, P.A. Cassileth: Phase II trial of didemnin
B in previously treated non-Hodgkin’s lymphoma: An Eastern cooperative oncology group
(ECOG) study, Am. J. Clin. Oncol. 23, 273–277
(2000)
32.31
B. Nuijen, M. Bouma, C. Manada, J.M. Jimeno,
J.H.M. Schellens, A. Bult, J.H. Beijnen: Pharmaceutical development of anticancer drugs derived
from marine sources, Anticancer Drugs 11, 793–811
(2000)
32.32
C.S. Mitsiades, E.M. Ocio, A. Pandiella, P. Maiso,
C. Gajate, M. Garayoa, D. Vilanova, J.C. Montero, N. Mitsiades, C.J. McMullan, N.C. Munshi,
T. Hideshima, D. Chauhan, P. Aviles, G. Otero,
G. Faircloth, M.V. Mateos, P.G. Richardson,
F. Mollinedo, J.F. San-Miguel, K.C. Anderson:
Aplidin, a marine organism-derived compound
with potent antimyeloma activity in vitro and in
vivo, Cancer Res. 68, 5216–5225 (2008)
32.33
C. Le Tourneau, E. Raymond, S. Faivre: Aplidine: A
paradigm of how to handle the activity and toxicity of a novel marine anticancer poison, Curr.
Pharm. Des. 13, 3427–3439 (2007)
32.34
W. Kem, F. Soti, K. Wildeboer, S. LeFrancois,
L. MacDougall, D.-Q. Wei, K.-C. Chou, H.R. Arias:
The nemertine toxin anabaseine and its deriative
DMXBA (GTS-21): Chemical and pharmacological
properties, Mar. Drugs 4, 255–273 (2006)
32.35
J.J. Buccafusco, S.R. Letchworth, M. Bencherif,
P.M. Lippiello: Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic
discordance, Trends Pharmacol. Sci. 26, 352–360
(2005)
32.36
H. Kitagawa, T. Takenouchi, R. Azuma, K.A. Wesnes, W.G. Kramer, D.E. Clody, A.L. Burnett: Safety,
pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male
volunteers, Neuropsychopharmacology 28, 542–
551 (2003)
32.37
A. Olincy, J.G. Harris, L.L. Johnson, V. Pender,
S. Kongs, D. Allensworth, K. Ellis, G.O. Zerbe,
S. Leonard, K.E. Stevens, J.O. Stevens, L. Martin, L.E. Adler, F. Soti, W.R. Kem, R. Freedman:
Proof-of-concept trial of an ˛7 nicotinic agonist
in schizophrenia, Arch. Gen. Psychiatr. 63, 630–
638 (2006)
32.38
R. Freedman, A. Olincy, R.W. Buchanan, J.G. Harris, J.M. Gold, L. Johnson, D. Allensworth,
A. Guzman-Bonilla, B. Clement, M.P. Ball, J. Kutnick, V. Pender, L.F. Martin, K.E. Stevens,
B.D. Wagner, G.O. Zerbe, F. Soti, W.R. Kem: Initial
Phase 2 trial of a nicotinic agonist in schizophrenia, Am. J. Psych. 165, 1040–1047 (2008)
32.39
B. Nicholson, G.K. Lloyd, B.R. Miller, M.A. Palladino, Y. Kiso, Y. Hayashi, S.T. Neuteboom:
NPI-2358 is a tubulin-depolymerizing agent: invitro evidence for activity as a tumor vasculardisrupting agent, Anticancer Drugs 17, 25–31
(2006)